Title : BCR-Abl Silencing by siRNA: A Potent Approach to Sensitize Chronic Myeloid Leukemia Cells to Tyrosine Kinase Inhibitor Therapy.

Pub. Date : 2019 Jun 1

PMID : 30585758






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In this study, we explored the feasibility of BCR-Abl siRNA therapy in CML K562 cells in vitro by employing a cationic polymer derived from cholesterol (Chol) grafted low-molecular weight polyethyleneimine (PEI). aziridine ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens